{"nctId":"NCT01650246","briefTitle":"Open-Label Lesinurad Monotherapy Extension Study in Gout","startDateStruct":{"date":"2012-08"},"conditions":["Gout"],"count":143,"armGroups":[{"label":"lesinurad 400 mg","type":"EXPERIMENTAL","interventionNames":["Drug: lesinurad"]}],"interventions":[{"name":"lesinurad","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study related activity.\n* Subject completed the double-blind treatment period in Study RDEA594-303 and was actively receiving and tolerating study medication (lesinurad or placebo) at Month 6 visit.\n* Subject is willing to adhere to the visit/protocol schedules.\n* Subject is male or female; female subjects of childbearing potential must agree to use an effective non-hormonal method of birth control during the study and for at least 14 days after the last dose of study medication.\n\nExclusion Criteria:\n\n* Subject has any other medical or psychological condition, which in the opinion of the Investigator and/or the Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or to complete the study.\n* Subject has a past medical history of urolithiasis, nephrolithiasis, or kidney stone diathesis.\n* Subject developed kidney stones during Study RDEA594-303","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Treatment-emergent Adverse Events (TEAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":143},"commonTop":["Blood creatinine increased","Upper respiratory tract infection","Hypertension","Gastroenteritis","Urinary tract infection"]}}}